bioAffinity Posts Big Growth
bioAffinity reported record CyPath Lung revenue and said volumes grew 99% in 2025, with unit growth accelerating into 2026 — a sign diagnostics with AI components are scaling quickly, reported. That growth underscores growing hospital and lab demand for AI‑assisted diagnostic tests.
The [company reported]investing.com $6.2 million in total revenue for 2025 (down from $9.4M in 2024) after management discontinued unprofitable pathology services, and it ended the year with $6.5 million in cash.investing.com [bioAffinity raised]ir.bioaffinitytech.com approximately $16.9 million in gross proceeds from equity financings in 2025 to fund CyPath® Lung commercialization, while physician ordering increased 67% year‑over‑year and the company cited early adoption within the U.S. Department of Veterans Affairs network.ir.bioaffinitytech.com The [company enrolled]investing.com its first patient in March 2026 for a planned longitudinal CyPath Lung study that aims to enroll up to 2,000 patients across 17 medical centers, and it announced a separate Brooke Army Medical Center collaboration for a 30–50 patient validation effort with results expected mid‑2026.investing.com [bioAffinity appointed]ir.bioaffinitytech.com Gordon Downie, MD, PhD as Chief Medical Officer and added Roberto Rios and John J. Oppenheimer to the board in 2025 as part of a leadership push tied to its strategic shift away from broader lab services toward scaling the CyPath® Lung diagnostic.ir.bioaffinitytech.com
